Deep Track Capital LP Has $11.49 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

Deep Track Capital LP reduced its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 37.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500,000 shares of the biopharmaceutical company's stock after selling 300,000 shares during the quarter. Deep Track Capital LP owned approximately 0.71% of Xencor worth $11,490,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. BVF Inc. IL grew its holdings in shares of Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock worth $52,596,000 after purchasing an additional 1,438,760 shares during the last quarter. Finepoint Capital LP acquired a new stake in Xencor in the 4th quarter valued at about $15,167,000. Vanguard Group Inc. raised its stake in shares of Xencor by 5.5% in the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock worth $184,239,000 after acquiring an additional 418,040 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Xencor by 21.3% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock worth $25,102,000 after purchasing an additional 192,080 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Xencor by 12.3% during the fourth quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock valued at $37,578,000 after purchasing an additional 179,526 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on XNCR shares. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research report on Wednesday, April 30th. Finally, William Blair started coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Xencor presently has an average rating of "Moderate Buy" and a consensus price target of $32.86.

Insider Buying and Selling at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the transaction, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. The trade was a 8.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.23% of the company's stock.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $8.46 on Wednesday. The company has a market capitalization of $601.95 million, a price-to-earnings ratio of -2.64 and a beta of 0.99. The firm's 50 day simple moving average is $11.11 and its 200 day simple moving average is $17.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million for the quarter, compared to analysts' expectations of $17.14 million. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.